NCT07798609
A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD
At risk: Primary completion moved at least 1 year 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion dates pushed to Aug 2029
- Start date changed from estimate of Sep 2026 to Oct 14, 2026
- Site contacts updated at 1 of 6 sites
- Minor Site contacts updated at 1 of 6 sites
- Minor Site details revised at 1 of 6 sites
- Notable Eligibility criteria expanded, about 7 words
- Secondary endpoints: 10 to 12
- Site contacts updated at 1 of 6 sites
- Minor Site details revised at 1 of 6 sitesv6
- Notable Recruitment opened
- Site details revised at 6 of 6 sites
- Minor Site contacts updated at 5 of 6 sitesv4
- Minor Site contacts updated at 1 of 6 sitesv3
- Minor Study sites: 7 to 6v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with treatment-emergent adverse events, serious adverse events, and any other dose-limiting toxicities as assessed by CTCAE v6.0.
Timeframe: Part A: Up to Week 24; Part B: Up to Week 48
Secondary (12)
Pharmacokinetics of SFL-0821: Maximum Observed Plasma Concentration (Cmax)
Pharmacokinetics of SFL-0821: Elimination half-life (T1/2 [h])
Pharmacokinetics of SFL-0821: Area under the concentration-time curve (AUC)
DUX4-regulated gene expression in skeletal muscle
Incidence of anti-drug antibodies (ADAs), and if positive, of neutralizing ADAs
Show 7 moreShow less
Change from Baseline in quantitative skeletal muscle magnetic resonance imaging (MRI) at the cohort specified timepoints after dosing
Change from Baseline to Week 48 in 10-Meter Walk-Run-Test (10MWRT)
Change from Baseline to Week 48 in Timed Up-and-Go (TUG) Test
Change from Baseline to Week 48 in 4-Step Stair Climb Test
Change from Baseline to Week 48 in Sit-to-Stand Test
Change from Baseline to Week 48 in Reachable Workspace (RWS)
Change from Baseline to Week 48 in quantitative muscle strength testing
Arms and interventions
SFL-0821Experimental
SFL-0821 for Injection
PlaceboPlacebo comparator
Placebo for Injection
Drugs: SFL-0821 for injection, Placebo
Sites
6 sites in 2 countries
Australia 5, New Zealand 1